Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations

被引：0
|
作者：
Popovici-Muller, Janeta [1 ]
Lemieux, Rene [2 ]
Saunders, Jeffrey [3 ]
Salituro, Francesco [4 ]
Yen, Katharine [1 ]
Straley, Kimberly [5 ]
Tobin, Erica [1 ]
Wang, Fang [1 ]
Gross, Stefan [1 ]
Artin, Erin [1 ]
Dang, Lenny [1 ]
Yang, Hua [1 ]
Utley, Luke [6 ]
Chen, Yue [1 ]
Olaharski, Andrew [1 ]
Silverman, Lee [1 ]
Agresta, Sam [1 ]
Su, Michael [1 ]
Biller, Scott [1 ]
机构：
[1] Agios Pharmaceut, Cambridge, MA USA
[2] KSQ Therapeut, Cambridge, MA USA
[3] Resilience Therapeut, Boston, MA USA
[4] Sage Therapeut, Cambridge, MA USA
[5] Vertex Pharmaceut, Boston, MA USA
[6] Alnylam Pharmaceut, Cambridge, MA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
268
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia
    Chaturvedi, Anuhar
    Gupta, Charu
    Goparaju, Ramya
    Gabdoulline, Razif
    Kaulfuss, Stefan
    Gorlich, Kerstin
    Schottmann, Renate
    Panknin, Olaf
    Wagner, Markus
    Geffers, Robert
    Ganser, Arnold
    Thol, Felicitas
    Jeffers, Michael
    Haegebarth, Andrea
    Heuser, Michael
    BLOOD, 2017, 130
  • [32] The mutant IDH1 inhibitor prevents growth of glioblastoma with IDH1 mutation in patient derived xenograft (PDX) model
    Machida, Yukino
    Ogawara, Yoko
    Ichimura, Koichi
    Matsunaga, Hironori
    Takahiko, Seki
    Araki, Kazushi
    Kitabayashi, Issay
    CANCER RESEARCH, 2016, 76
  • [33] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Doehner, Hartmut
    Martinelli, Giovanni
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du
    Wang, Xiwei
    Gong, Jing
    Kapsalis, Stephanie M.
    Hickman, Denice
    Zhang, Vickie
    Winkler, Thomas
    Daigle, Scott
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
  • [34] Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
    Lowery, Maeve Aine
    Abou-Alfa, Ghassan K.
    Burris, Howard A.
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer Saba
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Ishii, Yuko
    Auer, Julia
    Gliser, Camelia
    Agresta, Samuel V.
    Pandya, Shuchi Sumant
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] METHYLOMES AND TRANSCRIPTOMES VARY ACROSS IDH1 MUTANT CANCERS
    Scholtens, Denise
    Zewde, Makda
    Buss, Adam
    James, David
    Unruh, Dusten
    Horbinski, Craig
    NEURO-ONCOLOGY, 2018, 20 : 109 - 109
  • [36] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    De Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Mims, Alice S.
    Pollyea, Daniel A.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert H.
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, Will
    Pigneux, Arnaud
    Fathi, Amir T.
    Stein, Anthony S.
    Erba, Harry P.
    Prince, Gabrielle T.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Yen, Katharine
    Kapsalis, Stephanie M.
    Liu, Hua
    Goldwasser, Meredith
    Agresta, Sam
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [38] DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
    Ostrom, Quinn
    Xiu, Joanne
    Lopez, Giselle
    Sumrall, Ashley
    Aulakh, Sonikpreet
    Glantz, Michael
    Pan, Edward
    Khasraw, Mustafa
    Ashley, David M.
    Walsh, Kyle
    NEURO-ONCOLOGY, 2021, 23 : 13 - 14
  • [39] Recent advances of IDH1 mutant inhibitor in cancer therapy
    Tian, Wangqi
    Zhang, Weitong
    Wang, Yifan
    Jin, Ruyi
    Wang, Yuwei
    Guo, Hui
    Tang, Yuping
    Yao, Xiaojun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
    Chandhok, Namrata S.
    Wei, Wei
    Halene, Stephanie
    Prebet, Thomas
    BLOOD, 2019, 134
12345